Functionalized docetaxel-loaded lipid-based-nanosuspensions to enhance antitumor efficacy in vivo

References

• Keskin SK, Yildirim A, Canakci C, et al. The use of PSA doubling time to predict prognosis and the use of PSA response to assess the success for prostate cancer patients undergoing docetaxel chemotherapy. J Cancer Ther. 2016;07(08):593–599. doi:10.4236/jct.2016.78062
   Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med. 2015;373(17):1627–1639. doi:10.1056/NEJMoa150764326412456
   PubMed Web of Science ®Google Scholar
• Etrych T, Strohalm J, Šírová M, et al. High-molecular weight star conjugates containing docetaxel with high anti-tumor activity and low systemic toxicity in vivo. Polym Chem. 2015;6(1):160–170. doi:10.1039/C4PY01120A
   Web of Science ®Google Scholar
• Hu Q, Rijcken CJ, Bansal R, et al. Complete regression of breast tumour with a single dose of docetaxel-entrapped core-cross-linked polymeric micelles. Biomaterials. 2015;53:370–378. doi:10.1016/j.biomaterials.2015.02.08525890735
   PubMed Web of Science ®Google Scholar
• Khadka P, Ro J, Kim H, et al. Pharmaceutical particle technologies: an approach to improve drug solubility, dissolution and bioavailability. Asian J Pharm Sci. 2014;9(6):304–316.
   Google Scholar
• Kang JH, Ko YT. Lipid-coated gold nanocomposites for enhanced cancer therapy. Int J Nanomedicine. 2015;10:33–45.26345327
   PubMed Web of Science ®Google Scholar
• Su CY, Chen M, Chen LC, et al. Bispecific antibodies (anti-mPEG/anti-HER2) for active tumor targeting of docetaxel (DTX)-loaded mPEGylated nanocarriers to enhance the chemotherapeutic efficacy of HER2-overexpressing tumors. Drug Deliv. 2018;25(1):1066–1079. doi:10.1080/10717544.2018.147496729718725
   PubMed Web of Science ®Google Scholar
• Guo Y, Zhao S, Qiu H, et al. Shape of nanoparticles as a design parameter to improve docetaxel antitumor efficacy. Bioconjug Chem. 2018;29(4):1302–1311. doi:10.1021/acs.bioconjchem.8b0005929426226
   PubMedGoogle Scholar
• Khaliq NU, Park DY, Lee JY, et al. The multilayer nanoparticles for deep penetration of docetaxel into tumor parenchyma to overcome tumor microenvironment. Colloids Surf B Biointerfaces. 2016;146:833–840. doi:10.1016/j.colsurfb.2016.07.03427451372
   PubMedGoogle Scholar
• Marguerit G, Moustaoui H, Haddada MB, Djaker N, de la Chapelle ML, Spadavecchia J. Taxanes hybrid nanovectors: from design to physico-chemical evaluation of docetaxel and paclitaxel gold (III)-PEGylated complex nanocarriers. Part Part Syst Char. 2018;35(2):1700299. doi:10.1002/ppsc.v35.2
   Web of Science ®Google Scholar
• Jayaram DT, Ramos-Romero S, Shankar BH, et al. In vitro and in vivo demonstration of photodynamic activity and cytoplasm imaging through TPE nanoparticles. ACS Chem Biol. 2016;11(1):104–112. doi:10.1021/acschembio.5b0098726491952
   PubMedGoogle Scholar
• Gupta P, Singh M, Kumar R, et al. Synthesis and in vitro studies of PLGA-DTX nanoconjugate as potential drug delivery vehicle for oral cancer. Int J Nanomedicine. 2018;13:67–69. doi:10.2147/IJN.S17762729593398
   PubMedGoogle Scholar
• Danhier F. To exploit the tumor microenvironment: since the EPR effect fails in the clinic, what is the future of nanomedicine? J Control Release. 2016;244:108–121. doi:10.1016/j.jconrel.2016.11.01527871992
   PubMed Web of Science ®Google Scholar
• Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010;7(11):653–664. doi:10.1038/nrclinonc.2010.13920838415
   PubMed Web of Science ®Google Scholar
• Schleich N, Danhier F, Preat V. Iron oxide-loaded nanotheranostics: major obstacles to in vivo studies and clinical translation. J Control Release. 2015;198:35–54. doi:10.1016/j.jconrel.2014.11.02425481448
   PubMed Web of Science ®Google Scholar
• Belfiore L, Saunders DN, Ranson M, Thurecht KJ, Storm G, Vine KL. Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: challenges and opportunities. J Control Release. 2018;277:1–13. doi:10.1016/j.jconrel.2018.02.04029501721
   PubMed Web of Science ®Google Scholar
• Wang L, Li M, Zhang N. Folate-targeted docetaxel-lipid-based-nanosuspensions for active-targeted cancer therapy. Int J Nanomedicine. 2012;7:3281–3294. doi:10.2147/IJN.S3063122802688
   PubMed Web of Science ®Google Scholar
• Wang L, Liu Z, Liu D, et al. Docetaxel-loaded-lipid-based-nanosuspensions (DTX-LNS): preparation, pharmacokinetics, tissue distribution and antitumor activity. Int J Pharm. 2011;413(1–2):194–201. doi:10.1016/j.ijpharm.2011.04.02921540085
   PubMed Web of Science ®Google Scholar
• Wang TQ, Feng LX, Yang SM, et al. Ceramide lipid-based nanosuspension for enhanced delivery of docetaxel with synergistic antitumor efficiency. Drug Deliv. 2017;24(1):800–810. doi:10.1080/10717544.2016.126782228502199
   PubMed Web of Science ®Google Scholar
• Yan H, Wei P, Song J, et al. Enhanced anticancer activityin vitroandin vivoof luteolin incorporated into long-circulating micelles based on DSPE-PEG2000and TPGS. J Pharm Pharmacol. 2016;68(10):1290–1298. doi:10.1111/jphp.1259827465923
   PubMedGoogle Scholar
• Carter KA, Luo D, Razi A, et al. Sphingomyelin liposomes containing porphyrin-phospholipid for irinotecan chemophototherapy. Theranostics. 2016;6(13):2329–2336. doi:10.7150/thno.1570127877238
   PubMedGoogle Scholar
• Xie J, Yan C, Yan Y, et al. Multi-modal Mn–zn ferrite nanocrystals for magnetically-induced cancer targeted hyperthermia: a comparison of passive and active targeting effects. Nanoscale. 2016;8(38):16902–16915. doi:10.1039/C6NR03916B27427416
   PubMedGoogle Scholar
• David A. Peptide ligand-modified nanomedicines for targeting cells at the tumor microenvironment. Adv Drug Deliv Rev. 2017;119:120–142. doi:10.1016/j.addr.2017.05.00628506743
   PubMed Web of Science ®Google Scholar
• Zhang Z, Qian H, Huang J, et al. Anti-EGFR-iRGD recombinant protein modified biomimetic nanoparticles loaded with gambogic acid to enhance targeting and antitumor ability in colorectal cancer treatment. Int J Nanomedicine. 2018;13:4961–4975. doi:10.2147/IJN.S17762730214200
   PubMed Web of Science ®Google Scholar
• Muhamad N, Plengsuriyakarn T, Na-Bangchang K. Application of active targeting nanoparticle delivery system for chemotherapeutic drugs and traditional/herbal medicines in cancer therapy: a systematic review. Int J Nanomedicine. 2018;13:3921–3935. doi:10.2147/IJN.S17762730013345
   PubMed Web of Science ®Google Scholar
• Xie XY, Yang YF, Yang Y, Zhang H, Li Y, Mei X. A photo-responsive peptide- and asparagine–glycine–arginine (NGR) peptide-mediated liposomal delivery system. Drug Deliv. 2015;23:1–12. doi:10.3109/10717544.2015.1008707
   Web of Science ®Google Scholar
• Dunne M, Zheng J, Rosenblat J, Jaffray DA, Allen C. APN/CD13-targeting as a strategy to alter the tumor accumulation of liposomes. J Control Release. 2011;154(3):298–305. doi:10.1016/j.jconrel.2011.05.02221640146
   PubMed Web of Science ®Google Scholar
• Wang X, Wang Y, Chen X, Wang J, Zhang X, Zhang Q. NGR-modified micelles enhance their interaction with CD13-overexpressing tumor and endothelial cells. J Control Release. 2009;139(1):56–62. doi:10.1016/j.jconrel.2009.05.03019470394
   PubMedGoogle Scholar
• Negussie AH, Miller JL, Reddy G, Drake SK, Wood BJ, Dreher MR. Synthesis and in vitro evaluation of cyclic NGR peptide targeted thermally sensitive liposome. J Control Release. 2010;143(2):265–273. doi:10.1016/j.jconrel.2009.12.03120067811
   PubMed Web of Science ®Google Scholar
• Okamoto Y, Taguchi K, Yamasaki K, Sakuragi M, Kuroda S, Otagiri M. Effect of PEGylation on the physicochemical and pharmacokinetic characteristics of bovine serum albumin-encapsulated liposome. Asian J Pharm Sci. 2016;11(1):112–113. doi:10.1016/j.ajps.2015.11.101
   Google Scholar
• Riviere K, Kieler-Ferguson HM, Jerger K, et al. Anti-tumor activity of liposome encapsulated fluoroorotic acid as a single agent and in combination with liposome irinotecan. J Control Release. 2011;153(3):288–296. doi:10.1016/j.jconrel.2011.06.00321600250
   PubMed Web of Science ®Google Scholar
• Gao LY, Liu XY, Chen CJ, et al. Core-shell type lipid/rPAA-Chol polymer hybrid nanoparticles for in vivo siRNA delivery. Biomaterials. 2014;35(6):2066–2078. doi:10.1016/j.biomaterials.2014.01.02624315577
   PubMed Web of Science ®Google Scholar
• Lim SB, Banerjee A, Onyuksel H. Improvement of drug safety by the use of lipid-based nanocarriers. J Control Release. 2012;163(1):34–45. doi:10.1016/j.jconrel.2012.07.02822698939
   PubMed Web of Science ®Google Scholar
• Abdus Samad Y, Sultana Y, Aqil M. Liposomal drug delivery systems: an update review. Curr Drug Deliv. 2007;4(4):297–305. doi:10.2174/15672010778215126917979650
   PubMedGoogle Scholar
• Pasqualini R, Koivunen E, Kain R, et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis1. Cancer Res. 2000;60:722–727.10676659
   PubMed Web of Science ®Google Scholar